TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #14913 · Jul 3

#typescript#boilerplate#boilerplate_code#jamstack#javascript#js_boilerplate#netlify_template#next_js#next_theme#nextjs#nextjs_starter#nextjs_template#react#react_boilerplate#reactjs#starter_kit#starter_project#starter_template#tailwind_css#tailwindcss#typescript You can quickly start a modern web project using a ready-made Next.js boilerplate that includes the latest Next.js 15 features, Tailwind CSS 4, and TypeScript. It offers built-in user authentication, multi-language support, type-safe database tools, error monitoring, AI code reviews, and security features like bot protection. The setup is easy with local and remote database options, automatic testing, and deployment guides. This saves you time and effort by providing a flexible, production-ready foundation with best practices, letting you focus on building your app instead of configuring tools and infrastructure. It also supports smooth development with live reload and VSCode integration. https://github.com/ixartz/Next-js-Boilerplate

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment